Servier Pipeline

September 2025

SERVIER
moved by you

Oncology – solid tumors

Compound / MOA	Project	Therapeutic Area	Phase	Partner
Vorasidenib	S95032	Solid tumors	PCD 1 2 3	
Ivosidenib	S95031	Solid tumors (new indication)	PCD 1 2 3	
Darovasertib	S247629	Uveal melanoma	PCD 1 2 3	IDEAYA Biosciences
Vorasidenib + temozolomide	S95032	Solid tumors	PCD 1 2 3	
Vorasidenib + pembrolizumab	S95032	Solid tumors	PCD 1/2 3	
Ivosidenib + Durvalumab + Gemcitabine/Cisplatine	S95031	Solid tumors (new indication)	PCD 1/2 3	
Anti-TIM3 combo	S95018	Non-small Cell Lung Cancer	PCD 1/2 3	
Anti-CD73 combo	S95024	Non-small Cell Lung Cancer	PCD 1/2 3	
Anti-NKG2A combo	S95029	Non-small Cell Lung Cancer and Gastric cancer	PCD 1/2 3	
MAT2A inhibitor	S95035	Solid tumors	PCD 1 2 3	
RAF/RAS inhibitor	S241656	2nd line Non Small Cell Lung Cancer	PCD 1 2 3	
ND	S234821	Solid tumors	PCD 1 2 3	

Data as of September 2025

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, MOA = Mode of action, ND= Not disclosed

Oncology – Hematological malignancies

Compound / MOA	Project	Therapeutic Area	Phase	Partner
Ivosidenib combo 7+3 (chemo)	S95031	Hematological malignancies (new indication)	PCD 1 2 3	
Ivosidenib	S95031	Hematological malignancies (new indication)	PCD 1 2 3	
Calaspargase pegol combo	S95015	Hematological malignancies (new indication)	PCD 1 2 3	
Cemacabtagene ansegedleucel (Cema-Cel) Anti-CD19 Allogeneic CAR-T*	S95023*	Diffuse Large B-Cell Lymphoma	PCD 1 2 3	Licensed from Cellectis and Sub-Licensed to Allogene*
Menin inhibitor	S243249	R/R Acute Myeloid Leukemia and R/R Acute Lymphoblastic Leukemia with KMT2A rearrangement or NPM1 mutations	PCD 1 2 3	
ADC CD74-Mcl1 inihibitor + Venetoclax	S227928	R/R Acute Myeloid Leukemia and R/R Chronic Myelomonocytic Leukemia	PCD 1 2 3	Vernalis
ND	S236220	Hematological malignancies	PCD 1 2 3	

Data as of September 2025

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, MOA = Mode of action, ND= Not disclosed
R/R = Relapsed/Refractory

*Cema-Cel (ALLO501.A /S 95023) utilize TALEN® gene-editing technology owned by Cellectis. Servier, which has an exclusive license to the anti-CD19 investigational products from Cellectis, has granted Allogene exclusive rights to develop and commercialize Cema-Cel in the U.S., all EU Member States and the United Kingdom. For other candidate products (UCART19v1 and ALLO 501) sub-licensed to Allogene, the ongoing activities are limited to follow up of patients from discontinued trials as per regulatory obligations.

Neurology

NEUROLOGY

Compound / MOA	Project	Therapeutic Area	Phase	Partner
KCNT1 ASO	S230815	Developmental and Epileptic Encephalopathy	PCD 1 2 3	
BK channel modulator	S247240	Fragile X syndrome	PCD 1 2 3	
ND	S233107	Rare movement disorder	PCD 1 2 3	

Data as of September 2025

PCD = Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, MOA = Mode of action, ND= Not disclosed